Short Interest Update on Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NBIX) : The short interest in Neurocrine Biosciences (NBIX) has increased from 4,561,241 to 4,648,773 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 633,321 shares are traded daily in the stock and only 7 days are left for the shorts to cover. The short open interest is 5.4% of the total shares in the hands of the public. The shorts in the stock have gone up by 87,532 shares, which is an increase of 1.9% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Neurocrine Biosciences (NASDAQ:NBIX): The stock opened at $51.31 on Wednesday but the bulls could not build on the opening and the stock topped out at $53.46 for the day. The stock traded down to $49.28 during the day, due to lack of any buying support eventually closed down at $49.44 with a loss of -4.00% for the day. The stock had closed at $51.50 on the previous day. The total traded volume was 1,117,615 shares.


In a related news,The officer (Chief Medical Officer) of Neurocrine Biosciences Inc, Obrien Christopher Flint sold 12,500 shares at $48.73 on August 15, 2016. The Insider selling transaction had a total value worth of $609,125. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.